Selective CHK1 inhibitors may selectively sensitize p53 defective cancer cells to the cytotoxic effects of gemcitabine since p53 also plays a major role in checkpoint function for many anticancer therapeutics that cause DNA damage10,25,26. Here, TP53 is linked to cancer.